## Core Concept
The N-myc gene, also known as MYCN, is a proto-oncogene that when amplified or overexpressed, is commonly associated with aggressive forms of neuroblastoma, a type of cancer that primarily affects children. Neuroblastoma originates from the neural crest cells, which are precursors to the adrenal glands, sympathetic nervous system, and other tissues.

## Why the Correct Answer is Right
The correct answer, **D. Neuroblastoma**, is right because amplification of the N-myc gene is a well-established marker for poor prognosis in neuroblastoma. This genetic alteration leads to increased cell proliferation and survival, contributing to the aggressive behavior of the tumor. N-myc amplification is found in approximately 20% of neuroblastoma cases but is more commonly associated with advanced stages of the disease.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because while Wilms tumor (nephroblastoma) is a common renal malignancy in children, it is not typically associated with N-myc amplification. Instead, WT1 gene mutations are more commonly implicated in Wilms tumor.
- **Option B:** This option is incorrect because hepatoblastoma, a type of liver cancer in children, does not have a well-established link with N-myc amplification. Genetic alterations in hepatoblastoma often involve other genes and pathways.
- **Option C:** This option is incorrect because retinoblastoma, a malignancy of the retina in children, is primarily associated with mutations in the RB1 gene, not N-myc amplification.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that N-myc amplification in neuroblastoma not only correlates with a poorer prognosis but also influences treatment decisions. Patients with N-myc amplified neuroblastoma often require more aggressive chemotherapy and may benefit from targeted therapies. Remember, "N-myc amplification = Neuroblastoma with a nasty prognosis."

## Correct Answer Line
**Correct Answer: D. Neuroblastoma**